Nuvectis Pharma, Inc.

Contributing Author

Recent Articles by Nuvectis Pharma, Inc.

Nov-04	CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights NVCT GlobeNewswire
Nov-04	Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights NVCT GlobeNewswire
Oct-27	Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics NVCT GlobeNewswire
Oct-16	Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics NVCT GlobeNewswire
Sep-25	Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors NVCT GlobeNewswire
Sep-04	Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference NVCT GlobeNewswire
Aug-11	Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 NVCT GlobeNewswire
Aug-05	Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights NVCT GlobeNewswire
Jul-31	Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study NVCT GlobeNewswire
Jul-08	Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies NVCT GlobeNewswire
May-16	Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference NVCT GlobeNewswire
May-06	Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights NVCT GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.